Effectiveness of the recombinant human erythropoietin application in the anemia treatment of the burned patient.
Abstract
A longitudinal and experimental clinical test was carried out in a group of patients with anemia that received treatment with heberitro in plastic surgery and caumatology service from general university hospital Dr. Antonio Luaces Iraola in Ciego de Ávila, between January 2008 and January 2010 with the aim to determing the effectiveness of the Recombinant Human Erythropoietin application in the anemia treatment of the burned patient. The greater number of patients was registered in the ages between 30-34 years, predominating feminine sex. Patients reported very serious condition constituted most of the treated patients. The Heberitro dose increased in statistically significant way (p<0.05) the numbers of Hematocrit and Hemoglobin in the totality of cases and most of the cases required less red globule transfusion. Significant adverse events with the use of Heberitro were not reported. The average Hospital stay diminished.Downloads
Author Biographies
Bertha Luzardo Iglesias
Germán de Jesús Castillo Calderón
Eduardo Pina Morales
Bárbara M. Espinosa Machado
References
De los Santos CE. Guía básica para el tratamiento del paciente quemado. 2 ed. Santo Domingo: Cyberlibro; 2001.
Organización Mundial de la Salud. El uso clínico de la sangre. Manual de bolsillo. Ginebra: OMS; 2001.
Ira Zon L. The history of erithropoietin. En: Garnick MB, editor. Erythropoietin in Clinical Applications. New York: Elseiver; 2005. p. 1-27.
Jacobson LO, Goldwasser LF. Role of the kidney in erythropoiesis. Nature. 2007; 179:633-4.
Sabota TJ. Erythropoietin treatment of end-stage renal disease North American experience. En: Garnick MB, editor. Erythropoietin in clinical applications. New York: Elseiver; 2008. p. 1-27.
Scigalla P, Wieczorek L, Bicker V. Treatment of renal anemia with recombinant human erythropoietin: european experience. Nephrol Dial Transplant. 2004; 50:521-6.
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. Efficacy of recombinant human erythropoietin in critically ill patients. A randomized controlled trial. JAMA. 2008; 288:2827-35.
Morán Calvet MA. Características clinicoepidemiológicas de los accidentes por quemaduras en el municipio de Contramaestre. MEDISAN [Internet]. 2010 [citado 20 Sep 2012]; 14:3-10. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1029-30192010000300005&script=sci_arttext
Montes de Oca Campos I, Martínez Camejo JM, Calixté Semanat P, Selva Suárez AL. Autoagresión por quemaduras. Rev Cubana Med Gen Integr [Internet]. 1996 [citado 20 Sep 2012]; 12:2. Disponible en: http://scielo.sld.cu/scielo.php?pid=S0864-21251996000200002&script=sci_arttext
Barreiro Ramos H, Barreiro Peñaranda A, Viera Fernández E, Marrero Martín O. Quemaduras y etiología medicolegal. Rev Cubana Med Gen Integr [Internet]. 2006 [citado 20 Sep 2012]; 22:4. Disponible en: http://www.bvs.sld.cu/revistas/mgi/vol22_4_06/mgi07406.htm
Pruitt BA, McManus AT. The changing epidemiology of infection in burn patients. World J Surg. 1992;16:57
Singh AK, Szczech L, Tang LT, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2009; 355: 2085-2098.
Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol. 2007; 28(11):2430-6.
Bokemeyer C. European Organization for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007; 43(2):258-270.
Cabrera García L, Ruiz Antorán B, Sancho López A. Eritropoyetina: revisión de sus indicaciones. Inf Ter Sist Nac Salud. 2009; 33:3-9.
Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial: Crit Care Med. 2006; 34: 2310-6.
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. Efficacy of recombinant human erythropoietin in critically ill patients. A randomized controlled trial. JAMA. 2007; 288:2827-35.
The European Medicines Agency (EMEA). EMEA recommends a new warning for epoetins for their use in cancer patients [Internet]. London; 2008 [citado 12 Ene 2011] [aprox. 8 pantallas]. Disponible en: http://www.emea.europa.eu/pdfs/human/press/pr/33396308en.pdf
Pronzato P. Cancer-related anaemia management in the 21st century. Cancer Treat Rev. 2009; 32:S1– S3.
Voit T. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008; 108(2):317-325.
Stasi R. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncol. 2005; 10:539–554.
Pérez Oliva JF, Lagarte M, Herrera R, Enamorado A. EPOr Hu cubana, tolerancia, eficacia y beneficio. XIII Foro de Ciencia y Técnica. La Habana: Instituto de Nefrología; 1999. [Documento no publicado].
Donato H, Vain N, Rendo P, Vivas N, Prudent L, Larguia M, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial. Kidney Int. 2008; 61 (Suppl 80):55-61.
Delgado CA, Pineda L, Navarrete E. Manejo de pacientes quemados ingresados en la sala de cuidados intensivos del Hospital “Fernando Vélez Paiz”, Enero 2007-Diciembre 2008 [Internet]. 2009 [citado 12 Feb 2011] [aprox. 16 pantallas]. Disponible en: http://www.minsa.gob.ni/bns/monografias/2007/pediatria/Pacientes quemados S.pdf
Maier RF, Obladen M, Muller-Hansen I, Kattner E, Merz U, Arlettaz R, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr. 2007; 141(1):8-15.
Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer. 2008; 95(11):1467-73.
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.
The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.
